Novo Nordisk's sales growth will be negatively impacted in 2022
The pharmaceutical company's expectations for the consequences of the new Chinese procurement model for insulin have been released, and they are not good news for the firm.
by marketwire, translated by daniel pedersen
Novo Nordisk is predicting that global sales growth will be negatively impacted by 3 percent in 2022, it reports in a press release on Friday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
